Generate Biomedicines (NASDAQ:GENB) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Generate Biomedicines (NASDAQ:GENB) from a hold rating to a sell rating in a report issued on Saturday morning.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley increased their price objective on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. HC Wainwright increased their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Generate Biomedicines has an average rating of “Moderate Buy” and a consensus target price of $25.40.

Generate Biomedicines Stock Up 2.6%

Shares of GENB opened at $14.72 on Friday. The firm has a 50-day moving average of $14.48. The company has a market cap of $1.89 billion and a price-to-earnings ratio of -13.76. Generate Biomedicines has a 52-week low of $11.00 and a 52-week high of $18.18.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The company had revenue of $6.31 million for the quarter. As a group, research analysts anticipate that Generate Biomedicines will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Generate Biomedicines

An institutional investor recently bought a new position in Generate Biomedicines stock. Bank of New York Mellon Corp bought a new stake in shares of Generate Biomedicines Inc (NASDAQ:GENB) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 57,326 shares of the company’s stock, valued at approximately $967,000.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.